Altimmune's GLP-1/glucagon dual receptor agonist pemvidutide showed mixed results in its IMPACT Phase 2b MASH trial.
Although pemvidutide demonstrated statistically significant MASH resolution and some evidence of anti-fibrotic activity, it did not fully achieve the hoped-for level of fibrosis improvement.
Secondary endpoints showed 30.6% of patients on 1.8 mg pemvidutide had ≥60% reduction in fibrosis versus 8.2% on placebo, yet primary fibrosis endpoints were not met as strongly as anticipated.
Altimmune highlighted weight loss benefits (5–6.2% mean weight loss at 24 weeks) and a favorable tolerability profile.
Despite positive aspects, the results were not robust enough to fully deliver on fibrosis improvement promises, leading to mixed reactions from the market and analysts453.
Sources:
3. https://www.globenewswire.com/news-release/2025/06/26/3105697/0/en/Altimmune-Announces-Positive-Topline-Results-from-the-IMPACT-Phase-2b-Trial-of-Pemvidutide-in-the-Treatment-of-MASH.html
4. https://firstwordpharma.com/story/5976630
5. https://www.fiercebiotech.com/biotech/altimmunes-stock-sinks-mixed-phase-2-mash-results-glp-1-drug